share_log

舒泰神(300204.SZ):STSP-0902滴眼液I期临床试验完成首例受试者给药

staidson(300204.SZ): The first subject in the Phase I clinical trial of STSP-0902 eye drops was dosed.

Zhitong Finance ·  Oct 22, 2024 03:30

Staidson (300204.SZ) announcement, the company received the approval from the National Medical Products Administration in July 2024...

Zhitong Finance APP news, Staidson (300204.SZ) announcement, in July 2024, the company received the "Drug Clinical Trial Approval Notice" for STSP-0902 eye drops to treat neurotrophic keratitis, allowing the drug to conduct clinical trials for neurotrophic keratitis. Recently, the first subject in Phase I clinical trial for neurotrophic keratitis was dosed with STSP-0902 eye drops at Peking Union Medical College Hospital affiliated to Peking University Hospital.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment